Abstract
This double-blind placebo controlled, parallel design clinical trial compared the therapeutic effects of the addition of lithium or placebo to haloperidol in 21 seriously ill state hospital patients with DSM-III-R schizophrenia, who did not have concurrent affective disorders and who had not responded to previous trials of conventional antipsychotic medication. During a baseline period of 6 weeks, patients were switched to a stable dose of haloperidol (mean ± SD dose=13.6±8.1 mg/day). Patients were then randomized to receive either lithium or placebo in addition to haloperidol for 8 weeks (mean ± SD lithium level =0.98±0.13 mEq/1). Symptoms and side effects were assessed weekly. Improvement in symptoms correlated with the non-blind adjustment of antipsychotic dose, but not with lithium or placebo treatment. Side effects ratings did not differ between the two groups, but one patient developed a reversible delirium associated with combined lithium/haloperidol treatment. For these long-term, severely ill patients, combined treatment afforded no advantage over treatment with haloperidol alone.
Original language | English (US) |
---|---|
Pages (from-to) | 359-366 |
Number of pages | 8 |
Journal | Psychopharmacology |
Volume | 111 |
Issue number | 3 |
DOIs | |
State | Published - Jun 1993 |
Keywords
- Antipsychotic
- Haloperidol
- Lithium
- Schizophrenia
- Treatment resistant
ASJC Scopus subject areas
- Pharmacology